Vascular Endothelial Growth Factor (VEGF) Inhibitor Global Market will Exceed $13.98 Billion By 2028 with a Projected CAGR of 7.5% | Bayer AG, Astrazeneca Plc., Novartis AG, Pfizer Inc., Exelixis Inc.

The vascular endothelial growth factor (vegf) inhibitor market size has grown strongly in recent years. It will grow from $9.68 billion in 2023 to $10.46 billion in 2024 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to increase in cancer prevalence, strong economic growth in emerging markets, increase in pharmaceutical r&d expenditure, increased healthcare expenditure, government initiatives and rapid growth in elderly population.

The vascular endothelial growth factor (vegf) inhibitor market size is expected to see strong growth in the next few years. It will grow to $13.98 billion in 2028 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to increasing prevalence of cancer, rising prevalence of age-related macular degeneration (amd), rise in healthcare expenditure, high potential of emerging economies, high penetration of the biosimilar drugs and increasing geriatric population. Major trends in the forecast period include offering combination therapies to patients in order to combat advanced cancers and improve patient life, focusing on strategic collaborations to boost innovations and establish category leadership, investing extensively in r&d activities for the development of effective and innovative drugs, focusing on the production of biosimilars in order to cater to a wider market by making treatment more affordable and focusing on reducing dosages for wet age-related macular degeneration (amd) in order to improve patient welfare.

Market Overview -
A VEGF inhibitor is an inhibitor that prevents planned cell death by acting as an anti-apoptotic factor for hematopoietic cells. VEGF increases vascular permeability, which may make it easier for tumours to spread via the bloodstream and receive more oxygen and nutrients.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=3437&type=smp

The Increasing Prevalence Of Cancer And Macular Degeneration Diseases Drives The Vegf Inhibitor Market Growth.
The growing prevalence of cancer and macular degeneration diseases is expected to drive the VEGF inhibitor market. For instance, in August 2022, according to this systematic review and meta-analysis published by the National Library of Medicine, a US-based medical library, age-related macular degeneration will affect 8-7% of the global population, with the illness affecting 196 million individuals in 2020 and rising to 288 million by 2040. Anti-vascular endothelial growth factor (anti-VEGF) agents halt the progression of the disease and improve vision. A vascular endothelial growth factor (VEGF) inhibitor slows and restricts tumor growth during cancers. Hence, the rising prevalence of cancer along with macular degeneration disease aids in the vascular endothelial growth factor (VEGF) inhibitor market growth over the forecast period.

Competitive Landscape -
Major companies operating in the vascular endothelial growth factor (vegf) inhibitor market report are F. Hoffmann-La Roche AG, Bayer AG, Regeneron Pharmaceuticals Inc., Astrazeneca Plc., Novartis AG, Pfizer Inc., Eli Lilly and Company, Exelixis Inc., Amgen Inc., Sanofi S.A., Cipla Limited, Biocon, Dr. Reddy's Laboratories, Chi-Med, Innovent Biologics, Daiichi Sankyo, Chugai Pharmaceutical Co. Ltd, AstraZeneca plc, Allergan plc., Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Ipsen, Oxurion, AVEO Oncology, Pharmstandard Group, Zentiva, Coherus BioSciences Inc., Celgene, Exelixis Inc., Regeneron Pharmaceuticals Inc., AVEO pharmaceuticals, Eisai Co. Ltd.

Collaborations Drive Product Portfolio Expansion
Key players operating in the VEGF inhibitor industry are undergoing various collaborations and partnerships to expand their product portfolio by developing new products. Product portfolio expansion is the strategic approach that companies use to grow their businesses and increase their market share by satisfying consumer demand. The process of product development includes conceptualization, design, development, and marketing of newly created or newly rebranded goods or services. For instance, in September 2021, AbbVie, a US-based pharmaceutical company, partnered with REGENXBIO Inc., a US-based biotechnology company, to develop and commercialize RGX-314, an experimental gene therapy for chronic retinal illnesses such as diabetic retinopathy, wet age-related macular degeneration, and others. RGX-314 consists of the NAV AAV8 vector, which encodes an antibody fragment designed to inhibit vascular endothelial growth factor (VEGF). It is believed that RGX-314 blocks the VEGF pathway, which is responsible for the development of new, leaky blood vessels and the subsequent fluid buildup in the retina. In accordance with the terms of the contract, AbbVie will make a $370 million upfront payment to REGENXBIO, with the possibility of subsequent payments totaling up to $1.38 billion upon achievement of additional development, regulatory, and commercial milestones.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/vascular-endothelial-growth-factor-inhibitors-global-market-report

Key Segments -
The vascular endothelial growth factor (vegf) inhibitor market covered in this report is segmented -
1) By Drugs Type: Avastin, Tecentriq, Lucentis, Tagrisso, Cometriq, Eylea, Other Drug Types
2) By Route Of Administration: Oral, Intravenous, Intravitreal
3) By Application: Oncology, Ophthalmology, Other Applications

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model "

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.